Abstract:Introduction: Gut microbiota has emerged as a pivotal player in cardiovascular health and disease, extending its influence beyond the gut through intricate metabolic processes and interactions with the immune system. Accumulating evidence supports a significant association between gut microbiota and cardiovascular diseases such as atherosclerosis, hypertension, and heart failure. Dietary patterns have been identified as key factors shaping the composition of the gut microbiota and exerting notable impacts on cardiovascular health. Probiotics and prebiotics have shown promise in mitigating the risks of cardiovascular disease by modulating key cardiovascular parameters. Faecal microbiota transplantation (FMT) has recently emerged as a novel and intriguing therapeutic strategy. Aim: This review paper aims to explore and elucidate the multifaceted role of gut microbiota in cardiovascular health. It will also address the prevailing challenges and limitations in gut microbiota studies, emphasizing the importance of future research in overcoming these obstacles to expand our understanding of the gut-heart axis. Materials and methods: A comprehensive literature search was conducted using various databases including ClinicalTrials, Google Scholar, PubMed, ScienceDirect, MEDLINE, and Ovid Resources. The search strategy included utilizing keywords such as "Gut microbiota," "Randomized controlled trials (RCTs)," "Gut-heart axis," "Dysbiosis," "Diet," "Probiotics," "Prebiotics," "Faecal Microbiota transplantation," "cardiovascular disease," "Meta-analyses," and other compatible terms thereof. Only articles written in English were considered, and selection criteria included relevance to the research objectives, reasonable sample sizes, and robust methodology. In addition to the identified articles, meta-analyses, animal models and studies, and references from the selected articles were also examined to ensure a comprehensive review of the literature. Results: Dietary patterns exert a significant influence on the composition of the gut microbiota, and certain diets, such as the Mediterranean diet, have been associated with a favourable gut microbiota profile and a reduced risk of cardiovascular disease (CVD). Probiotics and prebiotics have emerged as potential interventions to mitigate CVD risks by modulating blood pressure, glycemic control, lipid profiles, and gut dysbiosis. Another innovative therapeutic approach is FMT, which involves transferring faecal material from a healthy donor to restore a balanced gut microbiota. FMT holds promise for improving cardiometabolic parameters in individuals with CVD, although further research is needed to elucidate its precise mechanisms and assess its effectiveness. Conclusion: The gut microbiota is emerging as a potential therapeutic target for CVD prevention and management. However, current research has limitations, including the need for larger and more diverse studies, the challenges of establishing causality, and concerns regarding the long-term consequences and safety of gut microbiota modulation. Despite these limitations, understanding the gut-heart axis holds promise for the development of personalized therapies and interventions for cardiovascular health. Further research is needed to expand our knowledge and address the ethical and safety issues associated with gut microbiota modification.

Gut Microbiota and Atrial Fibrillation: Pathogenesis, Mechanisms and Therapies

Does gut microbiota affect atrial rhythm? Causalities and speculations

Association of gut microbiome dysbiosis with the progression of atrial fibrillation: A systematic review

Gut Microbiota and Metabolites in Atrial Fibrillation Patients and Their Changes after Catheter Ablation

Different Types of Atrial Fibrillation Share Patterns of Gut Microbiota Dysbiosis

Gut microbiota-derived metabolites in atrial fibrillation: risk markers or modifiable risk factors?

Roles of gut microbiota in atrial fibrillation: insights from Mendelian randomization analysis and genetic data from over 430,000 cohort study participants

Gut Microbiota Dysbiosis Induced by a High-Fat Diet Increases Susceptibility to Atrial Fibrillation

Abstract 18307: Causal Association Between Gut Microbiota Composition and the Risk of Atrial Fibrillation

Altered synthesis of genes associated with short-chain fatty acids in the gut of patients with atrial fibrillation

Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives

Changes of the gut microbiota composition and short chain fatty acid in patients with atrial fibrillation

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease

GUT MICROBIOTA AND CARDIOMETABOLIC RISK FACTORS IN CORONARY ARTERY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

Disordered gut microbiota promotes atrial fibrillation by aggravated conduction disturbance and unbalanced Linoleic acid/SIRT1 signaling

Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State

The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation

Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review

Suppression of the gut microbiota–bile acid–FGF19 axis in patients with atrial fibrillation

Age-Related Changes in the Gut Microbiota Promote Atrial Fibrillation

Unveiling the relationship between gut microbiota and heart failure: Recent understandings and insights